Owkin's K Pro Autopilot agent proposed a KRAS G12D drug combination that widened eligible patients from about 10% to 60%.

Over 40% of pancreatic cancers carry KRAS G12D, but KRAS inhibitors lack durability and only about 10% of patients were eligible for combination therapy. K Pro's agentic Autopilot Mode ran lab-in-the-loop work to identify a new synthetic lethal vulnerability and a predicted combination. The page reports eligibility expanding from 10% to 60% and synergy confirmed in preclinical cell lines.

Owkin is a French AI company building biology models and the K Pro AI Scientist, working with pharma on drug positioning, trial design and pathology diagnostics.

This sits in the Build stage of the AI use-case lifecycle: Named examples from the foundation-model labs and platforms pharma teams use to actually construct, train and generate the model or application.